NY-ESO-1 Antibody as a Novel Tumour Marker of Gastric Cancer

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2013.51
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Induction of Primary NY-ESO-1 Immunity: CD8+ T Lymphocyte and Antibody Responses in Peptide-Vaccinated Patients With NY-ESO-1+ Cancers

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2000English

Serum Anti-P53 Antibody as a Tumour Marker for Colorectal Cancer Screening

ecancermedicalscience
Cancer ResearchOncology
2015English

NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer

PLoS ONE
Multidisciplinary
2012English

A Potential Role for Immunotherapy in Thyroid Cancer by Enhancing NY-ESO-1 Cancer Antigen Expression

Thyroid
MedicineEndocrinologyMetabolismDiabetes
2014English

NY-ESO-1 Is a Sensitive and Specific Immunohistochemical Marker for Myxoid and Round Cell Liposarcomas Among Related Mesenchymal Myxoid Neoplasms

Modern Pathology
Forensic MedicinePathology
2013English

NY-ESO-1 Antigen-Reactive T Cell Receptors Exhibit Diverse Therapeutic Capability

International Journal of Cancer
Cancer ResearchOncology
2012English

Preclinical Evaluation of Exemestane as a Novel Chemotherapy for Gastric Cancer

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

Identification of CD4+ T Cell Epitopes From NY-ESO-1 Presented by HLA-DR Molecules

Journal of Immunology
AllergyImmunology
2000English

Liver Receptor Homologue 1, a Novel Prognostic Marker in Colon Cancer Patients

Oncology Letters
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy